Buenos Aires
Breast Cancer
Symposium

BA-BCS 2024

September 3 – 6, 2024

IFIBYNE Auditorium, FCEN-UBA

Conferences

Opening
Conference

Robert Clarke

University of Manchester, Manchester, UK

The role of cytokines in regulating cancer stem cells in therapy-resistance and metastasis.

Conferences

Martin Abba

UNLP, La Plata, Argentina.

Old questions, new omics tools.

Fariba Behbod

University of Kansas, Kansas City, USA.University of Kansas, Kansas City, USA.University of Kansas, Kansas City, USA.

Ductal carcinoma in situ: Transcriptional diversity and stemness.Ductal carcinoma in situ: Transcriptional diversity and stemness.

Paolo Ceppi

University of Southern Denmark, Odense, Denmark.

Propionate suppresses epithelial-to-mesenchymal transition and reduces the aggressiveness of lung carcinoma, can we extrapolate to breast cancer?

Roger Chammas

Center for Translational Research in Oncology, University of São Paulo, Brazil.Center for Translational Research in Oncology, University of São Paulo, Brazil.

Circulating miRNAs as biomarkers for early onset triple negative breast cancer patients

Gonzalo Gomez Abuin

Hospital Alemán, Buenos Aires, Argentina.

Utility of next generation sequencing in breast cancer.

Vanesa Gottifredi

Instituto Leloir, Buenos Aires, Argentina.Instituto Leloir, Buenos Aires, Argentina.

Targeting the chromosomic instability induced by cancer therapy.

Joseph Jerry

University of Massachusetts, Amherst, USA.

A panel of normal breast epithelial cells from donors differing in breast cancer risk: variation in barriers to immortalization and estrogen signaling.

Dejan Juric

Massachusetts General Hospital, Boston, USA.

Novel PI3Ki inhibitors including mutant-selective PI3K inhibitors.

Adrian Lee

University of Pittsburgh, Pittsburgh, USA.

Endocrine resistance in breast cancer metastasis.

Paolo Mandó

CEMIC, Buenos Aires, Argentina.

Innovative Strategies in the Management of Triple-Negative Breast Cancer

Jochen Maurer

University Hospital RWTH, Aachen, Germany.

Cancer stem cells as disease models in research – opportunities and challenges.

Todd Miller

Medical College of Wisconsin Cancer Center, Milwaukee, USA.

Leveraging endocrine and metabolic vulnerabilities in ER+ breast cancer.

William Muller

Rosalind and Morris Goodman Cancer Center, Montreal, Canada.

Oncogene-mediated regulation of tumor immune microenvironment in mouse models of human breast cancer

Steffi Oestereich

University of Pittsburgh, Pittsburgh, USA.

Invasive lobular breast cancer – what’s different and why is this important?

Catherine Park

University of California, San Francisco, USA.University of California, San Francisco, USA.

The evolution of breast radiotherapy options for today’s early stage patients

Syril Pettit

Health and Environmental Sciences Institute (HESI), Washington DC, USA.

Addressing Cancer Therapy Related Adverse Effects – An Opportunity to Improve Quality of Life and Outcome for Patients.

Pedram Razavi

Memorial Sloan Kettering Cancer Center, New York City, USA.

Deciphering the genomic mechanisms of resistance to CDK4/6 inhibitors

Jennifer Richer

University of Colorado, Aurora, USA.

AR action in ER+ breast cancer – preclinical and clinical trial updates.

Adriana de Siervi

Oncoliq, CABA-Argentina.

miRNAs for early cancer detection in liquid biopsy.

María Vivanco

CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Breast Cancer heterogeneity and resistance to hormone therapy.

Federico Waisberg

Instituto Fleming, Buenos Aires, Argentina.

New treatments and biomarkers in hormone resistant (HR+) breast cancer.

Alana Welm

University of Utah, Salt Lake City, Utah, USA.

Using patient-derived models for drug discovery and functional precision oncology in advanced breast cancer.

Closing
Conference

Katherine Hoadley

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.

Molecular Characteristics of Metastatic Breast Cancer

© 2024 All Rights Reserved.